A Randomized, Double-Blind, Phase 1b Study to Assess the Safety and Activity of the HCV Entry Inhibitor ITX 5061 in Treatment-Naive HCV Mono-Infected Adults.
Phase of Trial: Phase I
Latest Information Update: 16 Sep 2013
At a glance
- Drugs ITX 5061 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 16 Sep 2013 Results published in the Journal of Infectious Diseases.
- 06 Mar 2013 Results presented at the 20th Conference on Retroviruses and Opportunistic Infections.
- 03 May 2012 Planned end date changed from 1 Oct 2012 to 1 Mar 2012 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History